<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>James Routley | Feed</title>
    <link
      rel="stylesheet"
      type="text/css"
      href="../styles.css"
      media="screen"
    />
  </head>
  <body>
    <a href="/index.html">Back</a>
    <a href="https://www.nber.org/papers/w34534">Original</a>
    <h1>Trials avoid high risk patients and underestimate drug harms</h1>
    
    <div id="readability-page-1" class="page"><div>
  <a id="main-content" tabindex="-1"></a>
        

  
  
        

<div>
  <div>
    
    
    
    <div>
        <p><span>Working Paper</span> 34534
  </p>

        <p><span>DOI</span> 10.3386/w34534
  </p>

        <p><span>Issue Date</span> <time datetime="2025-12-04T12:00:00Z">December 2025</time>

  </p>

          </div>
  </div>
  <div>
    <p>
The FDA does not formally regulate representativeness, but if trials under-enroll vulnerable patients, the resulting evidence may understate harm from drugs. We study the relationship between trial participation and the risk of drug-induced adverse events for cancer medications using data from the Surveillance, Epidemiology, and End Results Program linked to Medicare claims. Initiating treatment with a cancer drug increases the risk of hospitalization due to serious adverse events (SAE) by 2 percentage points per month (a 250% increase). Heterogeneity in SAE treatment effects can be predicted by patient&#39;s comorbidities, frailty, and demographic characteristics. Patients at the 90th percentile of the risk distribution experience a 2.5 times greater increase in SAEs after treatment initiation compared to patients at the 10th percentile of the risk distribution yet are 4 times less likely to enroll in trials. The predicted SAE treatment effects for the drug&#39;s target population are 15% larger than the predicted SAE treatment effects for trial enrollees, corresponding to 1 additional induced SAE hospitalization for every 25 patients per year of treatment. We formalize conditions under which regulating representativeness of SAE risk will lead to more externally valid trials, and we discuss how our results could inform regulatory requirements.
</p>
  </div>
  
</div>

  

  

<div>
  <ul>
          <li>
        
      </li>
    
    <li>
      <div>
    <div id="accordion-body-guid2" aria-labelledby="accordion-button-guid2">
        <p>Copy Citation</p>
        <div>
            <p>
                Jason Abaluck, Leila Agha, and Sachin Shah, &#34;Trials Avoid High Risk Patients and Underestimate Drug Harms,&#34; NBER Working Paper 34534 (2025), https://doi.org/10.3386/w34534.
            </p>

            </div>
                    <p>Download Citation</p>
            

            </div>
</div>    </li>

    
      </ul>
</div>


<section>
    
</section>


  
  
        <div>
    <div id="block-morefromthenber">
  
  
  <section>
    <h2>More from the NBER</h2>
    
    <div>
    

<div data-href="/research/videos/2025-17th-annual-feldstein-lecture-n-gregory-mankiw-fiscal-future">
      <p><img loading="lazy" src="https://blog.veitheller.de/sites/default/files/styles/promo/public/2025-07/MF%20Lecture%202025%20updated.png?itok=ij7zY5fj" width="736" height="414" alt=" 2025, 17th Annual Feldstein Lecture, N. Gregory Mankiw,&#34; The Fiscal Future&#34;" typeof="foaf:Image"/>



    </p>
  
  

      <ul>
      <li>Feldstein Lecture</li>
    </ul>
  
      <ul>
      <li>
        Presenter:
        

              <span>
      <a href="https://blog.veitheller.de/people/gregory_mankiw">N. Gregory Mankiw</a>    </span>
      
      </li>
    </ul>
  
  
  
      <p>N. Gregory Mankiw, Robert M. Beren Professor of Economics at Harvard University, presented the 2025 Martin Feldstein...</p>
  </div>

    

<div data-href="/research/videos/2025-methods-lecture-raj-chetty-and-kosuke-imai-uncovering-causal-mechanisms-mediation-analysis-and">
      <p><img loading="lazy" src="https://blog.veitheller.de/sites/default/files/styles/promo/public/2025-07/Methods%20Lecture%20SI%202025_0.png?itok=hsgorA8D" width="736" height="414" alt=" 2025 Methods Lecture, Raj Chetty, &#34;Uncovering Causal Mechanisms: Mediation Analysis and Surrogate Indices&#34;" typeof="foaf:Image"/>



    </p>
  
  

      <ul>
      <li>Methods Lectures</li>
    </ul>
  
      <ul>
      <li>
        Presenters:
        

              <span>
      <a href="https://blog.veitheller.de/people/raj_chetty">Raj Chetty</a>    </span>
                  <span>
       &amp; <a href="https://blog.veitheller.de/people/kosuke_imai">Kosuke Imai</a>    </span>
      
      </li>
    </ul>
  
  
  
      <p>SlidesBackground materials on mediationImai, Kosuke, Dustin Tingley, and Teppei Yamamoto. (2013). â€œExperimental Designs...</p>
  </div>

    

<div data-href="/research/videos/2025-international-trade-and-macroeconomics-panel-future-global-economy">
      <p><img loading="lazy" src="https://blog.veitheller.de/sites/default/files/styles/promo/public/2025-08/SI%20International%20trade%20Panel%202025.png?itok=2DuJTJDm" width="736" height="414" alt="2025 International Trade and Macroeconomics, &#34;Panel on The Future of the Global Economy&#34;" typeof="foaf:Image"/>



    </p>
  
  

      <ul>
      <li>Panel Discussion</li>
    </ul>
  
      <ul>
      <li>
        Presenters:
        

              <span>
      <a href="https://blog.veitheller.de/people/oleg_itskhoki">Oleg Itskhoki</a>,     </span>
                  <span>
      <a href="https://blog.veitheller.de/people/paul_krugman">Paul R. Krugman</a>    </span>
                  <span>
       &amp; <a href="https://blog.veitheller.de/people/linda_tesar">Linda Tesar</a>    </span>
      
      </li>
    </ul>
  
  
  
      <p>Supported by the Alfred P. Sloan Foundation grant #G-2023-19633, the Lynde and Harry Bradley Foundation grant #20251294...</p>
  </div>
</div>
  </section>
  
</div>
  </div>

  </div></div>
  </body>
</html>
